title: Conducting retrospective impact analysis to inform a medical research charity's funding strategies: the case of Asthma UK.
abstract: BACKGROUND
  Debate is intensifying about how to assess the full range of impacts from medical research. Complexity increases when assessing the diverse funding streams of funders such as Asthma UK, a charitable patient organisation supporting medical research to benefit people with asthma. This paper aims to describe the various impacts identified from a range of Asthma UK research, and explore how Asthma UK utilised the characteristics of successful funding approaches to inform future research strategies.
  
  
  METHODS
  We adapted the Payback Framework, using it both in a survey and to help structure interviews, documentary analysis, and case studies. We sent surveys to 153 lead researchers of projects, plus 10 past research fellows, and also conducted 14 detailed case studies. These covered nine projects and two fellowships, in addition to the innovative case studies on the professorial chairs (funded since 1988) and the MRC-Asthma UK Centre in Allergic Mechanisms of Asthma (the 'Centre') which together facilitated a comprehensive analysis of the whole funding portfolio. We organised each case study to capture whatever academic and wider societal impacts (or payback) might have arisen given the diverse timescales, size of funding involved, and extent to which Asthma UK funding contributed to the impacts.
  
  
  RESULTS
  Projects recorded an average of four peer-reviewed journal articles. Together the chairs reported over 500 papers. All streams of funding attracted follow-on funding. Each of the various categories of societal impacts arose from only a minority of individual projects and fellowships. Some of the research portfolio is influencing asthma-related clinical guidelines, and some contributing to product development. The latter includes potentially major breakthroughs in asthma therapies (in immunotherapy, and new inhaled drugs) trialled by university spin-out companies. Such research-informed guidelines and medicines can, in turn, contribute to health improvements. The role of the chairs and the pioneering collaborative Centre is shown as being particularly important.
  
  
  CONCLUSIONS
  We systematically demonstrate that all types of Asthma UK's research funding assessed are making impacts at different levels, but the main societal impacts from projects and fellowships come from a minority of those funded. Asthma UK used the study's findings, especially in relation to the Centre, to inform research funding strategies to promote the achievement of impact.
authors: Health Economics Research Group, Brunel University, Uxbridge UB8 3PH, UK. stephen.hanney@brunel.ac.uk.
authors: Stephen R
authors: SR
authors: Hanney
authors: Amanda
authors: A
authors: Watt
authors: Teresa H
authors: TH
authors: Jones
authors: Leanne
authors: L
authors: Metcalf
references: BMJ. 2001 Sep 8;323(7312):528
references: 11546684
references: Thorax. 2009 Jan;64(1):55-61
references: 19052047
references: Health Res Policy Syst. 2004 Jul 23;2(1):4
references: 15272939
references: BMJ. 2006 Dec 16;333(7581):1231-2
references: 17170394
references: J Allergy Clin Immunol. 2009 Sep;124(3):397-403
references: 19608262
references: N Engl J Med. 2002 May 30;346(22):1699-705
references: 12037149
references: Health Res Policy Syst. 2011 Jun 24;9:26
references: 21702930
references: Lancet. 1993 Apr 17;341(8851):989-90
references: 8096945
references: Lancet. 2002 Jul 6;360(9326):47-53
references: 12114041
references: Thorax. 2009 May;64 Suppl 1:i1-51
references: 19406863
references: Int J Technol Assess Health Care. 2008 Summer;24(3):259-69
references: 18601793
references: Allergy. 2008 Jan;63(1):5-34
references: 18053013
references: Chest. 2006 Jan;129(1 Suppl):75S-79S
references: 16428696
references: J Exp Med. 2005 Mar 21;201(6):937-47
references: 15781584
references: Health Technol Assess. 2007 Dec;11(53):iii-iv, ix-xi, 1-180
references: 18031652
references: Clin Exp Allergy. 2002 Apr;32(4):499-506
references: 11972593
references: Lancet. 2000 Jan 8;355(9198):119
references: 10675175
references: Am Rev Respir Dis. 1991 Oct;144(4):957-8
references: 1928974
references: Am Rev Respir Dis. 1991 May;143(5 Pt 1):1025-9
references: 1850964
references: N Engl J Med. 1999 Aug 12;341(7):468-75
references: 10441602
references: Health Res Policy Syst. 2003 Jan 13;1(1):2
references: 12646071
references: J Health Serv Res Policy. 1996 Jan;1(1):35-43
references: 10180843
references: Thorax. 2008 Nov;63(11):981-7
references: 18678701
references: Rheumatology (Oxford). 2005 Sep;44(9):1145-56
references: 16049052
references: Eur Respir J. 2006 Jan;27(1):29-35
references: 16387932
references: J Allergy Clin Immunol. 2007 Aug;120(2):381-7
references: 17560637
references: J Clin Invest. 2006 Jan;116(1):146-55
references: 16341266
references: Nature. 2010 Jun 10;465(7299):665-6
references: 20535155
references: J Exp Med. 1994 Mar 1;179(3):881-7
references: 7509365
references: Health Res Policy Syst. 2010 May 13;8:11
references: 20465789
references: Clin Exp Allergy. 2008 Jan;38(1):19-42
references: 18081563
references: Clin Exp Allergy. 2005 Sep;35(9):1175-9
references: 16164444